GlassScriptPhysician profile
Philip Bauman
NPI 1457348872
$1,744.72
in general payments reported to CMS, 2019-2025
20 companies · $349 in 2025
The $349 reported for 2025 was more than what 88% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $45.81 · 2021: $185 · 2022: $271 · 2023: $348 · 2024: $366 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,063.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $291.47 | 2019-2025 | Bexsero, Pediarix, Penmenvy |
| Merck Sharp & Dohme LLC | $264.73 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Pfizer INC. | $244.91 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $208.53 | 2019-2024 | Jornay Pm |
| Corium, LLC | $128.87 | 2022-2024 | Azstarys |
| Cranial Technologies, INC | $110.25 | 2021-2025 | Doc Band |
| Sanofi-Aventis U.S. LLC | $81.35 | 2024-2025 | |
| Kaleo, INC. | $65.05 | 2019-2022 | |
| Alk-Abello, INC | $45.67 | 2025 | Neffy |
| Collegium Pharmaceutical, INC. | $41.23 | 2025 | Jornay Pm |
| Sanofi Pasteur INC. | $37.56 | 2023 | |
| Supernus Pharmaceuticals, INC. | $37.40 | 2021-2022 | |
| Tris Pharma INC | $37.00 | 2020-2023 | Dyanavel Xr |
| Biomerieux INC | $31.00 | 2025 | |
| Biomarin Pharmaceutical INC. | $25.88 | 2025 | Voxzogo 1.2mg |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $25.59 | 2023 | Elaprase |
| Nestle Healthcare Nutrition INC. | $21.49 | 2023 | |
| Alexion Pharmaceuticals, INC. | $17.00 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.50 | 2025 | Zoryve |
| Seqirus USA INC | $14.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Bauman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.